Histone Modifications is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Histone modifications are post-translational chemical alterations to histone proteins that regulate chromatin structure and gene expression without changing the DNA sequence. These epigenetic modifications - including acetylation, methylation, phosphorylation, ubiquitination, and sumoylation - control the accessibility of DNA to transcriptional machinery and play fundamental roles in neuronal gene expression, synaptic plasticity, and memory formation. In neurodegenerative diseases, widespread dysregulation of histone modifications contributes to aberrant gene expression programs that promote neuroinflammation, synaptic loss, and neuronal death (Nativio et al., 2020).
Histone deacetylase ([HDAC] inhibitors have emerged as promising therapeutic candidates for Alzheimer's disease, Parkinson's disease, Huntington's disease, and ALS, with several compounds advancing through preclinical and clinical development (Shukla & Singh, 2024).
DNA in the nucleus is packaged around histone octamers to form nucleosomes, the fundamental units of chromatin:
- Core histones: Two copies each of H2A, H2B, H3, and H4 form the octamer
- DNA wrapping: ~147 bp of DNA wraps ~1.65 turns around each octamer
- Linker histone: H1 binds linker DNA between nucleosomes, compacting higher-order chromatin structure
- Histone tails: N-terminal tails protrude from the nucleosome and are the primary targets for post-translational modifications
The "histone code hypothesis" proposes that specific combinations of histone modifications create a code read by effector proteins to regulate gene expression:
- Euchromatin (open, transcriptionally active): Associated with acetylation, H3K4me3, H3K36me3
- Heterochromatin (closed, transcriptionally silent): Associated with deacetylation, H3K9me3, H3K27me3
- Bivalent domains: Carry both activating (H3K4me3) and repressive (H3K27me3) marks; "poised" for rapid activation or silencing
The most studied histone modification in neurodegeneration:
Mechanism:
- Addition of acetyl groups to lysine residues on histone tails
- Writers: Histone acetyltransferases (HATs) - CBP/p300, PCAF, GCN5, Tip60
- Erasers: Histone deacetylases (HDACs) - 18 mammalian HDACs in 4 classes
- Readers: Bromodomain-containing proteins (BRD2, BRD4)
Effect: Neutralizes the positive charge on lysine, weakening histone-DNA interactions and opening chromatin for transcription.
Key acetylation marks in the brain:
| Mark |
Location |
Function |
Change in AD |
| H3K9ac |
Promoters |
Gene activation |
Globally decreased |
| H3K14ac |
Promoters |
Gene activation |
Decreased |
| H3K27ac |
Enhancers, promoters |
Active enhancer mark |
Redistributed |
| H4K16ac |
Gene bodies |
Transcription elongation |
Decreased |
| H4K12ac |
Promoters |
Memory-related gene expression |
Decreased with aging |
Mechanism:
- Addition of methyl groups to lysine or arginine residues
- Writers: Histone methyltransferases (HMTs) - SET-domain proteins (EZH2, G9a, SUV39H1), DOT1L
- Erasers: Histone demethylases (HDMs) - LSD1, JMJD family
- Readers: Chromodomain, Tudor domain, PHD finger proteins
- Can be mono-, di-, or trimethylated (each with distinct functions)
Key methylation marks:
- H3K4me3: Activating mark at promoters; decreased at memory genes in AD
- H3K9me2/3: Repressive mark; increased at neuroprotective genes in AD
- H3K27me3: Polycomb-mediated silencing; altered in neurodegeneration
- H3K36me3: Transcription elongation; mark of actively transcribed genes
- H4K20me3: Constitutive heterochromatin; involved in DNA damage response
- Addition of phosphate groups to serine, threonine, or tyrosine residues
- H3S10ph: Associated with mitotic chromosome condensation and immediate-early gene activation
- gamma-H2AX (H2AXS139ph): DNA double-strand break marker; increased in AD and ALS neurons, indicating elevated DNA damage
- Catalyzed by kinases (Aurora B, MSK1, ATM) and removed by phosphatases
- H2AK119ub: Polycomb-mediated transcriptional repression (PRC1 complex)
- H2BK120ub: Required for H3K4 and H3K79 methylation; facilitates transcription
- Altered in Huntington's disease due to mutant huntingtin interactions with the ubiquitin-proteasome system
Large-scale chromatin profiling studies have revealed widespread histone modification changes in AD brains:
- H3K27ac redistribution: Nativio et al. (2020) performed genome-wide H3K27ac profiling in AD brains and found massive redistribution rather than simple loss - enhancers at immune/inflammatory genes gain acetylation while neuronal/synaptic gene enhancers lose acetylation (Nativio et al., 2020)
- H3K9ac loss: Global decrease in H3K9 acetylation at promoters of synaptic plasticity and memory genes
- H4K16ac reduction: Associated with chromatin compaction and gene silencing in AD
- H3K4me3 changes: Altered at promoters of tau]-related and inflammatory genes
- [HDAC] upregulation: Several HDACs (HDAC2, HDAC3, HDAC6) are elevated in AD brains
- HAT loss: CBP/p300 activity decreases with amyloid-beta and tau] pathology
- Oxidative modification: reactive oxygen species directly modify histones and epigenetic enzymes
- Tau-mediated heterochromatin loss: Tau interacts with heterochromatin and its loss leads to aberrant gene expression, including retrotransposon activation
- Inflammatory signaling: NF-κB activation recruits HATs to inflammatory gene promoters while HDACs are redirected from neuronal genes
- HDAC2: Upregulated in AD hippocampal neurons; negatively regulates memory gene expression; its knockdown restores synaptic plasticity and memory in AD mice (Graff et al., 2012)
- HDAC3: Negative regulator of memory consolidation; elevated in AD
- HDAC6: Deacetylates tau] and alpha-tubulin; promotes tau aggregation; inhibition reduces tau pathology
- SIRT1 (Class III [HDAC: Neuroprotective; decreases in AD brains; activates alpha
- Mutant huntingtin sequesters CBP/p300 (HAT) in aggregates, causing global hypoacetylation
- HDAC inhibitors (SAHA, sodium butyrate) improve motor and cognitive phenotypes in HD mice
- H3K4me3 is reduced at neuronal identity genes in HD striatum
- HD is the neurodegenerative disease with the strongest evidence for epigenetic therapies
- TDP-43 and FUS interact with histone-modifying complexes
- Increased H2AX phosphorylation (gamma-H2AX) indicates DNA damage in motor neurons
- HDAC6 inhibition improves axonal transport and motor function in ALS models
- C9orf72 repeat expansions alter chromatin structure at the repeat locus
HDAC inhibitors are the most advanced epigenetic therapeutic strategy for neurodegeneration:
| Compound |
HDAC Selectivity |
Status |
Key Evidence |
| Vorinostat (SAHA) |
Pan-HDAC (I, II) |
FDA-approved (cancer) |
Improves memory in AD mice; restores histone acetylation |
| Sodium valproate |
Class I/IIa |
FDA-approved (epilepsy) |
Clinical trials in AD; mixed results |
| CI-994 (Tacedinaline) |
Class I selective |
Preclinical (AD) |
Restores hippocampal memory gene expression |
| Tubastatin A |
HDAC6 selective |
Preclinical |
Reduces tau phosphorylation and aggregation |
| RGFP966 |
HDAC3 selective |
Preclinical |
Enhances memory consolidation |
| Compound 3 |
HDAC11 selective |
Preclinical (2025) |
Brain-penetrant; colocalizes with amyloid plaques |
- Selectivity: Pan-HDAC inhibitors affect thousands of genes; isoform-selective inhibitors are preferred
- Cell-type specificity: Different cell types require different epigenetic programs; systemic HDAC inhibition may be harmful
- BBB penetration: Many HDAC inhibitors have poor blood-brain barrier permeability
- Side effects: Hematological toxicity, GI effects, fatigue
- Dosing: Therapeutic window between efficacy and toxicity is narrow
- Irreversibility concerns: Some epigenetic changes may be difficult to reverse once established
- BET bromodomain inhibitors: Block readers of acetylated histones; reduce inflammatory gene expression
- EZH2 inhibitors: Target H3K27me3 writer; may reactivate silenced neuroprotective genes
- LSD1 inhibitors: Block histone demethylase; restore H3K4me at memory genes
- CRISPR-based epigenetic editing: Targeted modification of histone marks at specific genomic loci (experimental)
- Dual-target inhibitors: Compounds targeting both RIPK1 and HDACs for combined anti-inflammatory and epigenetic effects (2024-2025 development)
The study of Histone Modifications has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [Nativio R, et al. An integrated multi-omics approach identifies epigenetic alterations associated with Alzheimer's Disease. Nat Genet. 2020;52(10]:1024-1035. DOI
- [Graff J, et al. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature. 2012;483(7388]:222-226. DOI
- [Shukla S, Singh SS. Restoring the epigenome in Alzheimer's Disease: advancing HDAC inhibitors as therapeutic agents. Drug Discov Today. 2024;29(8]:104056. [PMID: 38830501]https://pubmed.ncbi.nlm.nih.gov/38830501/)
- [Guan JS, et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature. 2009;459(7243]:55-60. DOI
- [Peleg S, et al. Altered histone acetylation is associated with age-dependent memory impairment in mice. Science. 2010;328(5979]:753-756. DOI
- [Konsoula Z, Bhatt AB. Epigenetics in neurodegenerative diseases. Biomolecules. 2024;16(1]:103. DOI
- [Zheng Y, et al. The role of histone modifications: from neurodevelopment to neurodiseases. Signal Transduct Target Ther. 2022;7(1]:217. DOI
- [Stilling RM, Fischer A. The role of histone acetylation in age-associated memory impairment and Alzheimer's Disease. Neurobiol Learn Mem. 2011;96(1]:19-26. DOI
- [Fischer A, et al. Recovery of learning and memory is associated with chromatin remodelling. Nature. 2007;447(7141]:178-182. DOI
- [Chuang DM, et al. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 2009;32(11]:591-601. DOI
- [Frost B, et al. Tau promotes neurodegeneration through global chromatin relaxation. Nat Neurosci. 2014;17(3]:357-366. DOI
- [Cook C, et al. Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Hum Mol Genet. 2014;23(1]:104-116. DOI